Gender differences in cardiovascular disease: Hormonal and biochemical influences

Reproductive Sciences

Volumn 17, Issue 6, 2010, Pages 511-531

  Pérez López, Faustino R ^a   Larrad Mur, Luis ^a   Kallen, Amanda ^b   Chedraui, Peter ^c   Taylor, Hugh S ^b  

^a UNIVERSITY OF ZARAGOZA   (Spain)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSIDAD CATÓLICA DE SANTIAGO DE GUAYAQUIL   (Ecuador)

Author keywords

Atherosclerosis; Cardiovascular disease; Factors; Gender.; Hormones

Indexed keywords

ADIPONECTIN; ALDOSTERONE; ANDROGEN; ANDROSTENEDIONE; ANGIOTENSIN; CONJUGATED ESTROGEN; CYPROTERONE ACETATE; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FLUTAMIDE; GESTAGEN; HIGH DENSITY LIPOPROTEIN; INSULIN; LEPTIN; LOW DENSITY LIPOPROTEIN; NITRIC OXIDE; PLACEBO; PRASTERONE SULFATE; PROSTACYCLIN; PROSTANOID; RENIN; RESISTIN; SEX HORMONE; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE; VASCULOTROPIN; VITAMIN D;

ATHEROSCLEROSIS; BIOCHEMISTRY; BLOOD VESSEL WALL; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; EXTRACELLULAR MATRIX; FEMALE; HEREDITY; HORMONE SUBSTITUTION; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; MALE; MENOPAUSE; NONHUMAN; OBESITY; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW; SEX DIFFERENCE; SMOOTH MUSCLE FIBER; STROKE; VASCULAR ENDOTHELIUM; VASODILATATION;

ANDROGENS; ANIMALS; CARDIOVASCULAR DISEASES; ESTRADIOL; FEMALE; HUMANS; MALE; SEX FACTORS;

EID: 77952390469     PISSN: 19337191     EISSN: 19337205     Source Type: Journal    
DOI: 10.1177/1933719110367829     Document Type: Review

References (239)

1. Okey R., Stewart D. Diet and blood cholesterol in normal women. J Biol Chem. 1932 ; 99 (3). 717, 1933.
2. Anonymous. Hormones and atherosclerosis. Meeting in Utah. BMJ. 1958 ; 1 (5078). 1059-1060.
3. Bonneux L., Barendregt JJ Ischaemic heart disease and cholesterol. Theres more to heart disease than cholesterol. BMJ. 1994 ; 308 (6935). 1038, 1041.
4. Ravnskov U. Ischaemic heart disease and cholesterol. Optimism about drug treatment is unjustified. BMJ. 1994 ; 308 (6935). 1038, 1041.
5. Marín A., Medrano MJ, González J., et al. Risk of ischaemic heart disease and acute myocardial infarction in a Spanish population: observational prospective study in a primary-care setting. BMC Public Health. 2006 ; 6: 38.
6. Law MR, Wald NJ, Rudnicka AR Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ. 2003 ; 326 (7404). 1423.
7. Brunzell JD Clinical practice. Hypertriglyceridemia. N Engl J Med. 2007 ; 357 (10). 1009-1017.
8. Lieb W., Larson MG, Benjamin EJ, et al. Multimarker approach to evaluate correlates of vascular stiffness: the Framingham Heart Study. Circulation. 2009 ; 119 (1). 37-43.
9. Ridker PM, Danielson E., Fonseca FA, et al, for the JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008 ; 359 (21). 2195-2207.
10. Glynn RJ, MacFadyen JG, Ridker PM Tracking of high-sensitivity C-reactive protein after an initially elevated concentration: the JUPITER Study. Clin Chem. 2009 ; 55 (2). 305-312.
11. González-Clemente JM, Giménez-Palop O., Vilardell C., Caixàs A., Giménez-Pérez G. Are statins analogues of vitamin D? Lancet. 2006 ; 368 (9543). 1233.
12. Pérez-Castrillón JL, Vega G., Abad L., et al. Effects of atorvastatin on vitamin D levels in patients with acute ischemic heart disease. Am J Cardiol. 2007 ; 99 (7). 903-905.
13. Penttinen J. Hypothesis: low serum cholesterol, suicide, and interleukin-2. Am J Epidemiol. 1995 ; 141 (8). 716-718.
14. Hillbrand M., Waite BM, Miller DS, Spitz RT, Lingswiler VM Serum cholesterol concentrations and mood states in violent psychiatric patients: an experience sampling study. J Behav Med. 2000 ; 23 (6). 519-529.
15. Marcoff L., Thompson PD The role of coenzyme Q10 in statin-associated myopathy: a systematic review. J Am Coll Cardiol. 2007 ; 49 (23). 2231-2237.
16. Phillips GB Is atherosclerotic cardiovascular disease an endocrinological disorder? The estrogen-androgen paradox. J Clin Endocrin Metab. 2005 ; 90 (5). 2708-2711.
17. Wannamethee SG, Tchernova J., Whincup P., et al. Plasma leptin: associations with metabolic, inflammatory and haemostatic risk factors for cardiovascular disease. Atherosclerosis. 2007 ; 191 (2). 418-426.
18. Michos ED, Melamed ML Vitamin D and cardiovascular disease risk. Curr Opin Clin Nutr Metab Care. 2008 ; 11 (1). 7-12.
19. Pérez-López FR Vitamin D metabolism and cardiovascular risk factors in postmenopausal women. Maturitas. 2009 ; 62 (3). 248-262.
20. Perez-Lopez FR, Chedraui P., Gilbert J., Perez-Roncero G. Cardiovascular risk in menopausal women and prevalent related comorbid conditions: facing the post-WHI era. Fertil Steril. 2009 ; 92 (4). 1171-1186.
21. Kinder L., Carnethon M., Palaniappan L., King A., Fortmann S. Depression and the metabolic syndrome in young adults: findings from the National Health and Nutrition Examination Survey. Psychosom Med. 2004 ; 66 (3). 316-322.
22. Fatourechi V. Subclinical hypothyroidism: an update for primary care physicians. Mayo Clin Proc. 2009 ; 84 (1). 65-71.
23. Evangelista O., McLaughlin M. Review of cardiovascular risk factors in women. Gend Med. 2 009; 6 (1). 17-36.
24. Mankad R., Best P. Cardiovascular disease in older women: a challenge in diagnosis and treatment. Womens Health. 2008 ; 4 (5). 449-464.
25. Kaseta JR, Skafar DF, Ram JL, Jacober SJ, Sowers JR Cardiovascular disease in the diabetic woman. J Clin Endocrinol Metab. 1999 ; 84 (6). 1835-1838.
26. Lorenzo C., Williams K., Hunt KJ, Haffner SM. The National Cholesterol Education Program-Adult Treatment Panel III, International Diabetes Federation, and World Health Organization definitions of the metabolic syndrome as predictors of incident cardiovascular disease and diabetes. Diabetes Care. 2007 ; 30 (1). 8-13.
27. Shearman AM, Cooper JA, Kotwinski PJ, et al. Estrogen receptor alpha gene variation is associated with risk of myocardial infarction in more than seven thousand men from five cohorts. Circ Res. 2006 ; 98 (5). 590-592.
28. Hodges YK, Tung L., Yan XD, Graham JD, Horwitz KB, Horwitz LD Estrogen receptors alpha and beta: prevalence of estrogen receptor beta mRNA in human vascular smooth muscle and transcriptional effects. Circulation. 2000 ; 101 (15). 1792-1798.
29. Schuit SC, Oei HH, Witteman JC, et al. Estrogen receptor alpha gene polymorphisms and risk of myocardial infarction. JAMA. 2004 ; 291 (24). 2969-2977.
30. Schuit SC, de Jong FH, Stolk L., et al. Estrogen receptor alpha gene polymorphisms are associated with estradiol levels in postmenopausal women. Eur J Endocrinol. 2005 ; 153 (2). 327-334.
31. Liu PY, Christian RC, Ruan M., Miller VM, Fitzpatrick LA Correlating androgen and estrogen steroid receptor expression with coronary calcification and atherosclerosis in men without known coronary artery disease. J Clin Endocrinol Metab. 2005 ; 90 (2). 1041-1046.
32. Christian RC, Liu PY, Harrington S., Ruan M., Miller VM, Fitzpatrick LA Intimal estrogen receptor (ER) beta, but not ER alpha expression, is correlated with coronary calcification and atherosclerosis in pre- and postmenopausal women. J Clin Endocrinol Metab. 2006 ; 91 (7). 2713-2720.
33. Lindner V., Kim SK, Karas RH, Kuiper GG, Gustafsson JA, Mendelsohn ME Increased expression of estrogen receptor-beta mRNA in male blood vessels after vascular injury. Circ Res. 1998 ; 83 (2). 224-229.
34. Rexrode KM, Ridker PM, Hegener HH, Buring JE, Manson JAE, Zee RYL. Polymorphisms and haplotypes of the estrogen receptor-?2 gene (ESR2) and cardiovascular disease in men and women. Clin Chem. 2007 ; 53 (10). 1749-1756.
35. Domingues-Montanari S., Subirana I., Tomás M., Marrugat J., Sentí M. Association between ESR2 genetic variants and risk of myocardial infarction. Clin Chem. 2008 ; 54 (7). 1183-1189.
36. Goulart AC, Zee RY, Rexrode KM Association of estrogen receptor 2 gene polymorphisms with obesity in women (obesity and estrogen receptor 2 gene). Maturitas. 2009 ; 62 (2). 179-183.
37. Haas E., Bhattacharya I., Brailoiu E., et al. Regulatory role of G protein-coupled estrogen receptor for vascular function and obesity. Circ Res. 2009 ; 104 (3). 288-291.
38. Mårtensson UE, Salehi SA, Windahl S., et al. Deletion of the G protein-coupled receptor 30 impairs glucose tolerance, reduces bone growth, increases blood pressure, and eliminates estradiol-stimulated insulin release in female mice. Endocrinology. 2009 ; 150 (2). 687-698.
39. Barrett-Connor E., Bush TL Estrogens and coronary heart disease in women. JAMA. 1991 ; 265 (14). 1861-1867.
40. Reckelhoff JF Gender differences in the regulation of blood pressure. Hypertension. 2001 ; 37 (5). 1199-1208.
41. Ho JE, Paultre F., Mosca L. The gender gap in coronary heart disease mortality: is there a difference between blacks and whites ? J Womens Health (Larchmt). 2005 ; 14 (2). 117-127.
42. Perez Lopez F., Cuadros-Lopez J., Fernadez A., Cuadros-Celorrio A., Sabatel-Lopez R., Chedraui P. Assessing fatal cardiovascular disease with the SCORE scale in postmenopausal women 10 years after different hormonal treatment regimens. Gynecological Endocrinology. http://www.gynecologicalendocrinology. org/services/journal.htm. Posted online on 17 Nov 2009.
43. Lemieux S., Després JP, Moorjani S., et al. Are gender differences in cardiovascular disease risk factors explained by the level of visceral adipose tissue ? Diabetologia. 1994 ; 37 (8). 757-764.
44. Tomaszewski M., Charchar FJ, Maric C., et al. Association between lipid profile and circulating concentrations of estrogens in young men. Atherosclerosis. 2009 ; 203 (1). 257-262.
45. Mohlke KL, Boehnke M., Abecasis GR Metabolic and cardiovascular traits: an abundance of recently identified common genetic variants. Hum Mol Genet. 2008 ; 17 (R2). R102 - R108.
46. Okada M., Nomura S., Ikoma Y., Yamamoto E., Ito T., Matsui T., Tamakoshi K., Mizutani S. Effects of postmenopausal hormone therapy on hemoglobin A1C levels. Diabetes Care. 2003 ; 26 (4). 1088-1092.
47. Johnson J., Slentz C., Duscha B., et al. Gender and racial differences in lipoprotein subclass distributions: the STRRIDE study. Atherosclerosis. 2004 ; 176 (2). 371-377.
48. Otvos JD, Collins D., Freedman DS, et al. Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial. Circulation. 2006 ; 113 (12). 1556-1563.
49. Persson J., Nilsson J., Lindholm MW Cytokine response to lipoprotein lipid loading in human monocyte-derived macrophages. Lipids Health Dis. 2006 ; 5: 17.
50. Rifici VA, Khachadurian AK The inhibition of low-density lipoprotein oxidation by 17 ?2-estradiol. Metabolism. 1992 ; 41 (10). 1110-1114.
51. Negre-Salvayre A., Pieraggi MT, Mabile L., Salvayre R. Protective effect of 17-8-estradiol against the cytotoxicity of minimally oxidized LDL to cultured bovine aortic endothelial cells. Atherosclerosis. 1993 ; 99 (2). 209-217.
52. Huber LA, Scheffler E., Poll T., Ziegler R., Dresel HA 17 Beta-estradiol inhibits LDL oxidation and cholesterol ester formation in cultured macrophages. Free Radic Res Commun. 1990 ; 8 (3). 167-173.
53. Lloyd-Jones DM, ODonnell CJ, DAgostino RB, Massaro J., Silbershatz H., Wilson PW Applicability of cholesterol-lowering primary prevention trials to a general population: the Framingham heart study. Arch Intern Med. 2001 ; 161 (7). 949-954.
54. Third Report of the National Cholesterol Education Program (NCEP). Detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Circulation. 2002 ; 106 (25). 3143-3421.
55. Shlipak MG, Simon JA, Vittinghoff E., et al. Estrogen and progestin, lipoprotein(a) and the risk of recurrent coronary heart disease events after menopause. JAMA. 2000 ; 283 (14). 1845-1852.
56. VaidYa D., Dobs A., Gapstur SM, et al. The association of endogenous sex hormones with lipoprotein subfraction profile in the Multi-Ethnic Study of Atherosclerosis. Metabolism. 2008 ; 57 (6). 782-790.
57. Freedman DS, Otvos JD, Jeyarajah EJ, et al. Sex and age differences in lipoprotein subclasses measured by nuclear magnetic resonance spectroscopy: the Framingham Study. Clin Chem. 2004 ; 50 (7). 1189-1200.
58. Rossouw JE, Anderson GL, Prentice RL, et al, for the Writing Group for the Womens Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Womens Health Initiative randomized controlled trial. JAMA. 2002 ; 288 (3). 321-333.
59. Anderson G., Limacher M., Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the WHI RCT. JAMA. 2004 ; 291 (14). 1701-1712.
60. Turgeon J., McDonnell D., Martin K., Wise P. Hormone therapy: physiological complexity belies therapeutic simplicity. Science. 2004 ; 304 (5676). 1269-1273.
61. Naftolin F., Taylor HS, Karas R., et al, for the Womens Health Initiative. The Womens Health Initiative could not have detected cardioprotective effects of starting hormone therapy during the menopausal transition. Fertil Steril. 2004 ; 81 (6). 1498-1501.
62. Manson JE, Allison MA, Rossouw JE, et al. Estrogen therapy and coronary-artery calcification. N Engl J Med. 2007 ; 356 (25). 2591-2602.
63. Egbrink MG, Van Gestel MA, Broeders MA, et al. Regulation of microvascular thromboembolism in vivo. Microcirculation. 2005 ; 12 (3). 287-300.
64. Maffei S., Mercuri A., Prontera C., Zucchelli GC, Vassalle C. Vasoactive biomarkers and oxidative stress in healthy recently postmenopausal women treated with hormone replacement therapy. Climacteric. 2006 ; 9 (6). 452-458.
65. Taddei S., Virdis A., Ghiadoni L., Versari D., Salvetti A. Endothelium, aging, and hypertension. Curr Hypertens Rep. 2006 ; 8 (1). 84-89.
66. Byar DP Proceedings: the Veterans Administration Cooperative Urological Research Groups studies of cancer of the prostate. Cancer. 1973 ; 32 (5). 1126-1130.
67. Akkad AA, Halligan AW, Abrams K., al- Azzawi F. Differing responses in blood pressure over 24 hours in normotensive women receiving oral or transdermal estrogen replacement therapy. Obstet Gynecol. 1997 ; 89 (1). 97-103.
68. Harmon S., Brinton E., Cedars M., et al. KEEPS: The Kronos Early Estrogen Prevention Study. Climacteric. 2005 ; 8 (1). 3-12.
69. Farhat MY, Lavigne MC, Ramwell PW The vascular protective effects of estrogen. FASEB J. 1996 ; 10 (5). 615-624.
70. Skafar DF, Xu R., Morales J., Ram J., Sowers JR Female sex hormones and cardiovascular disease in women. J Clin Endocrinol Metab. 1997 ; 82 (12). 3913-3918.
71. Simoncini T., Mannella P., Fornari L., et al. Differential signal transduction of progesterone and medroxyprogesterone acetate in human endothelial cells. Endocrinology. 2004 ; 145 (12). 5745-5756.
72. Kublickiene K., Svedas E., Landgren BM, et al. Small artery endothelial dysfunction in postmenopausal women: in vitro function, morphology, and modification by estrogen and selective estrogen receptor modulators. J Clin Endocrinol Metab. 2005 ; 90 (11). 6113-6122.
73. Rossouw JE, Prentice PL, Manson JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA. 2007 ; 297 (13). 1465-1477.
74. Rivera CM, Grossardt BR, Rhodes DJ, et al. Increased cardiovascular mortality after early bilateral oophorectomy. Menopause. 2009 ; 16 (1). 15-23.
75. Nelson LM Primary ovarian insufficiency. N Engl J Med. 2009 ; 360 (6). 606-614.
76. Parker WH, Manson JE Oophorectomy and cardiovascular mortality: is there a link?. Menopause 2009 ; 16 (1). 1-2.
77. Collins P. Vascular effect of hormones. Maturitas. 2001 ; 38 (1). 45-51.
78. Schnoes KK, Jaffe IZ, Iyer L., et al. Rapid recruitment of temporally distinct vascular gene sets by estrogen. Mol Endocrinol. 2008 ; 22 (11). 2544-2556.
79. Peter I., Kelley-Hedgepeth A., Huggins GS, et al. Association between arterial stiffness and variations in oestrogen-related genes. J Hum Hypertens. 2009 ; 23 (10). 636-644.
80. Williams JK, Delansorne R., Paris J. Estrogens, progestins and coronary artery reactivity in atherosclerotic monkeys. J Steroid Biochem Mol Biol. 1998 ; 65 (1-6). 219-224.
81. Mendelsohn ME Genomic and nongenomic effects of estrogen in the vasculature. Am J Cardiol. 2002 ; 90 (1A). 3F - 6F.
82. Teoh H., Quan A., Leung SW, Man RY Vascular effects of estrone and diethylstilbestrol in porcine coronary arteries. Menopause. 2009 ; 16 (1). 104-109.
83. Mercuro G., Zoncu S., Saiu F., Mascia M., Melis GB, Rosano GM Menopause induced by oophorectomy reveals a role of ovarian estrogen on the maintenance of pressure homeostasis. Maturitas. 2004 ; 47 (2). 131-138.
84. Ichikawa J., Sumino H., Ichikawa S., Ozaki M. Different effects of transdermal and oral hormone replacement therapy on the renin-angiotensin system, plasma bradykinin level, and blood pressure of normotensive postmenopausal women. Am J Hypertens. 2006 ; 19 (7). 744-749.
85. Mueck AO, Seeger H. Effect of hormone therapy on BP in normotensive and hypertensive postmenopausal women. Maturitas. 2004 ; 49 (3). 189-203.
86. Vongpatanasin W., Tuncel M., Mansour Y., Arbique D., Victor RG Transdermal estrogen replacement therapy decreases sympathetic activity in postmenopausal women. Circulation. 2001 ; 103 (24). 2903-2908.
87. Haas E., Meyer MR, Schurr U., et al. Differential effects of 17beta-estradiol on function and expression of estrogen receptor alpha, estrogen receptor beta, and GPR30 in arteries and veins of patients with atherosclerosis. Hypertension. 2007 ; 49 (6). 1358-1363.
88. Tech H., Quan A., Leung S. Vascular effects of estrone and DES in porcine coronary arteries. Menopause. 2009 ; 16 (1). 104-109.
89. Barton M., Cremer J., Mügge A. 17Beta-estradiol acutely improves endothelium-dependent relaxation to bradykinin in isolated human coronary arteries. Eur J Pharmacol. 1998 ; 362 (1). 73-76.
90. Lewis DA, Avsar M., Labreche P., Bracamonte M., Jayachandran M., Miller VM Treatment with raloxifene and 17beta-estradiol differentially modulates nitric oxide and prostanoids in venous endothelium and platelets of ovariectomized pigs. J Cardiovasc Pharmacol. 2006 ; 48 (5). 231-238.
91. Liu PY, Death AK, Handelsman DJ Androgens and cardiovascular disease. Endocr Rev. 2003 ; 24 (3). 313-340.
92. Rexrode KM, Ridker PM, Hegener HH, Buring JE, Manson JE, Zee RY Genetic variation of the androgen receptor and risk of myocardial infarction and ischemic stroke in women. Stroke. 2008 ; 39 (5). 1590-1592.
93. Davison SL, Bell R., Donath S., Montalto JG, Davis SR Androgen levels in adult females: Changes with age, menopause, and oophorectomy. J Clin Endocrinol Metab. 2005 ; 90 (7). 3847-3853.
94. Yeap BB Are declining testosterone levels a major risk factor for ill-health in aging men? Int J Impot Res. 2009 ; 21 (1). 24-36.
95. Yeap BB, Hyde Z., Almeida OP, et al. Lower testosterone levels predict incident stroke and transient ischemic attack in older men. J Clin Endocrinol Metab. 2009 ; 94 (7). 2353-2359.
96. Mukherjee TK, Dinh H., Chaudhuri G., Nathan L. Testosterone attenuates expression of vascular cell adhesion molecule-1 by conversion to estradiol by aromatase in endothelial cells: implications in atherosclerosis. Proc Natl Acad Sci U S A. 2002 ; 99 (6). 4055-4060.
97. Teoh H., Quan A., Leung SW, Man RY Differential effects of 17beta-estradiol and testosterone on the contractile responses of porcine coronary arteries. Br J Pharmacol. 2000 ; 129 (7). 1301-1308.
98. Traish AM, Saad F., Feeley RJ, Guay AT The dark side of testosterone deficiency: III. Cardiovascular disease. J Androl. 2009 ; 30 (5). 477-494.
99. Diano S., Horvath TL, Mor G., et al. Aromatase and estrogen receptor immunoreactivity in the coronary arteries of monkeys and human subjects. Menopause. 1999 ; 6 (1). 21-28.
100. Valkenburg O., Steegers-Theunissen RP, Smedts HP, et al. A more atherogenic serum lipoprotein profile is present in women with polycystic ovary syndrome: a case-control study. J Clin Endocrinol Metab. 2008 ; 93 (2). 470-476.
101. Luque-Ramírez M., Mendieta-Azcona C., Alvarez-Blasco F., Escobar-Morreale HF Androgen excess is associated with the increased carotid intima-media thickness observed in young women with polycystic ovary syndrome. Hum Reprod. 2007 ; 22 (12). 3197-3203.
102. Shaw LJ, Bairey Merz CN, Azziz R., et al. Postmenopausal women with a history of irregular menses and elevated androgen measurements at high risk for worsening cardiovascular event-free survival: results from the National Institutes of Health-National Heart, Lung, and Blood Institute sponsored Womens Ischemia Syndrome Evaluation. J Clin Endocrinol Metab. 2008 ; 93 (4). 1276-1284.
103. Florakis D., Diamanti-Kandarakis E., Katsikis I., et al. Effect of hypocaloric diet plus sibutramine treatment on hormonal and metabolic features in overweight and obese women with polycystic ovary syndrome: a randomized, 24-week study. Int J Obes (Lond). 2008 ; 32 (4). 692-699.
104. Maturana MA, Breda V., Lhullier F., Spritzer PM Relationship between endogenous testosterone and cardiovascular risk in early postmenopausal women. Metabolism. 2008 ; 57 (7). 961-965.
105. Barrett-Connor EL, Goodman-Gruen D. Prospective study of endogenous sex hormones and fatal cardiovascular disease in postmenopausal women. Br Med J. 1995 ; 311 (7014). 1193-1196.
106. Ding EL, Song Y., Manson JE, Rifai N., Buring JE, Liu S. Plasma sex steroid hormones and risk of developing type 2 diabetes in women: a prospective study. Diabetologia. 2007 ; 50 (10). 2076-2084.
107. Khatibi A., Agardh CD, Shakir YA, et al. Could androgens protect middle-aged women from cardiovascular events? A population-based study of Swedish women: The Womens Health in the Lund Area (WHILA) Study. Climacteric. 2007 ; 10 (5). 386-392.
108. Page G., Goulart A., Rexrode K. Interrelation between sex hormones and plasma SHBG and HbA1C in healthy postmenopausal women. Metab Syndr Relat Disord. 2009 ; 7 (3). 249-254.
109. Bernini GP, Moretti A., Sgró M., et al. Influence of endogenous androgens on carotid wall in postmenopausal women. Menopause. 2001 ; 8 (1). 43-50.
110. Golden SH, Maguire A., Ding J., et al. Endogenous postmenopausal hormones and carotid atherosclerosis: a case-control study of the atherosclerosis risk in communities cohort. Am J Epidemiol. 2002 ; 155 (5). 437-445.
111. Debing E., Peeters E., Duquet W., Poppe K., Velkeniers B., Van den Brande P. Endogenous sex hormone levels in postmenopausal women undergoing carotid artery endarterectomy. Eur J Endocrinol. 2007 ; 156 (6). 687-693.
112. Liu D., Dillon JS Dehydroepiandrosterone stimulates nitric oxide release in vascular endothelial cells: evidence for a cell surface receptor. Steroids. 2004 ; 69 (4). 279-289.
113. Ling S., Dai A., Williams MR, et al. Testosterone (T) enhances apoptosis-related damage in human vascular endothelial cells. Endocrinology. 2002 ; 143 (3). 1119-1125.
114. Formoso G., Chen H., Kim JA, Montagnani M., Consoli A., Quon MJ Dehydroepiandrosterone mimics acute actions of insulin to stimulate production of both nitric oxide and endothelin 1 via distinct phosphatidylinositol 3-kinase- and mitogen-activated protein kinase-dependent pathways in vascular endothelium. Mol Endocrinol. 2006 ; 20 (5). 1153-1163.
115. Galley HF, Webster NR Physiology of the endothelium. Brit J Anaesth. 2004 ; 93 (1). 105-113.
116. Vane JR, Anggard EE, Botting RM Regulatory functions of the vascular endothelium. N Engl J Med. 1990 ; 323 (1). 27-36.
117. Thambyrajah J., Townend JN Homocysteine and atherothrombosis-mechanisms for injury. Eur Heart J. 2000 ; 21 (12). 967-974.
118. Vallance P., Collier J., Moncada S. Effects of endothelium-derived nitric oxide on peripheral arteriolar tone in man. Lancet. 1989 ; 2 (8670). 997-1000.
119. Sase K., Michel T. Expression of constitutive endothelial nitric oxide synthase in human blood platelets. Life Sci. 1995 ; 57 (22). 2049-2055.
120. Chen LY, Mehta JL Further evidence of the presence of constitutive and inducible nitric oxide synthase isoforms in human platelets. J Cardiovasc Pharmacol. 1996 ; 27 (1). 154-158.
121. Arnal JF, Douin-Echinard V., Brouchet L., et al. Understanding the oestrogen action in experimental and clinical atherosclerosis. Fundam Clin Pharmacol. 2006 ; 20 (6). 539-548.
122. Hisamoto K., Ohmichi M., Kurachi H., et al. Estrogen induces the Akt-dependent activation of endothelial nitric-oxide synthase in vascular endothelial cells. J Biol Chem. 2001 ; 276 (5). 3459-3467.
123. Selles J., Polini N., Alvarez C., Massheimer V. Progesterone and 17 beta-estradiol acutely stimulate nitric oxide synthase activity in rat aorta and inhibit platelet aggregation. Life Sci. 2001 ; 69 (7). 815-827.
124. Tsutsumi S., Zhang X., Takata K., et al. Differential regulation of the inducible nitric oxide synthase gene by estrogen receptors 1 and 2. J Endocrinol. 2008 ; 199 (2). 267-273.
125. Zhu Y., Bian Z., Lu P., et al. Abnormal vascular function and hypertension in mice deficient in estrogen receptor ?2. Science. 2002 ; 295 (5554). 505-508.
126. Buchwalow IB, Cacanyiova S., Neumann J., Samoilova VE, Boecker W., Kristek F. The role of arterial smooth muscle in vasorelaxation. Biochem Biophys Res Commun. 2008 ; 377 (2). 504-507.
127. Vita JA, Treasure CB, Nabel EG, et al. Coronary vasomotor response to acetylcholine relates to risk factors for coronary artery disease. Circulation. 1990 ; 81 (2). 491-497.
128. Watts GF, OBrien SF, Silvester W., Millar JA Impaired endothelium-dependent and independent dilatation of forearm resistance arteries in men with diet-treated non-insulin-dependent diabetes: role of dyslipidaemia. Clin Sci (Colch). 1996 ; 91 (5). 567-573.
129. Uittenbogaard A., Shaul PW, Yuhanna IS, Blair A., Smart EJ High density lipoprotein prevents oxidized low density lipoprotein-induced inhibition of endothelial nitric-oxide synthase localization and activation in caveolae. J Biol Chem. 2000 ; 275 (15). 11278-11283.
130. OConner BJ, Genest J. Jr. High-density lipoproteins and endothelial function. Circulation. 2001 ; 104 (16). 1978-1983.
131. Ferrara N., Gerber HP The role of vascular endothelial growth factor in angiogenesis. Acta Haematol. 2002 ; 106 (4). 148-156.
132. Matsumoto T., Mugishima. Signal transduction via vascular endothelial growth factor (VEGF) receptors and their roles in atherogenesis. J Atheroscler Thromb. 2006 ; 13 (3). 130-135.
133. Shibuya M. Differential roles of vascular endothelial growth factor receptor-1 and receptor-2 in angiogenesis. J Biochem Mol Biol. 2006 ; 39 (5). 469-478.
134. Shizukuda Y., Tang S., Yokota R., Ware JA Vascular endothelial growth factor-induced endothelial cell migration and proliferation depend on a nitric oxide-mediated decrease in protein kinase Cdelta activity. Circ Res. 1999 ; 85 (3). 247-256.
135. Lal BK, Varma S., Pappas PJ, Hobson RW 2nd, Durán WN VEGF increases permeability of the endothelial cell monolayer by activation of PKB/akt, endothelial nitric-oxide synthase, and MAP kinase pathways. Microvasc Res. 2001 ; 62 (3). 252-262.
136. Leek RD, Hunt NC, Landers RJ, Lewis CE, Royds JA, Harris AL Macrophage infiltration is associated with VEGF and EGFR expression in breast cancer. J Pathol. 2000 ; 190 (4). 430-436.
137. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med. 1999 ; 340 (2). 115-126.
138. Jonasson L., Holm J., Skalli O., Bondjers G., Hansson GK Regional accumulations of T cells, macrophages, and smooth muscle cells in the human atherosclerotic plaque. Arteriosclerosis. 1986 ; 6 (2). 131-138.
139. Häkkinen T., Karkola K., Ylä-Herttuala S. Macrophages, smooth muscle cells, endothelial cells, and T-cells express CD40 and CD40L in fatty streaks and more advanced human atherosclerotic lesions. Colocalization with epitopes of oxidized low-density lipoprotein, scavenger receptor, and CD16 (Fc gammaRIII). Virchows Arch. 2000 ; 437 (4). 396-405.
140. Clauss M., Gerlach M., Gerlach H., et al. Vascular permeability factor: a tumor-derived polypeptide that induces endothelial cells and monocyte procoagulant activity, and promotes monocyte migration. J Exp Med. 1990 ; 172 (6). 1535-1545.
141. Barleon B., Sozzani S., Zhou D., Weich HA, Mantovani A., Marmé D. Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the receptor Flt-1. Blood. 1996 ; 87 (8). 3336-3343.
142. Celletti FL, Waugh JM, Amabile PG, Brendolan A., Hilfiker PR, Dake MD Vascular endothelial growth factor enhances atherosclerotic plaque progression. Nat Med. 2001 ; 7 (4). 425-429.
143. Lopez JJ, Laham RJ, Stamler A., et al. VEGF administration in chronic myocardial ischemia in pigs. Cardiovasc Res. 1998 ; 40 (2). 272-281.
144. Lazarous DF, Shou M., Scheinowitz M., et al. Comparative effects of basic fibroblast growth factor and vascular endothelial growth factor on coronary collateral development and the arterial response to injury. Circulation. 1996 ; 94 (5). 1074-1082.
145. Pérez-López FR, Chedraui P., Haya J., Cuadros JL Effects of the Mediterranean diet pattern on longevity and age-prevalent morbid conditions. Maturitas. 2009 ; 64 (2). 67-79.
146. Oak MH, Chataigneau M., Keravis T., et al. Red wine polyphenolic compounds inhibit vascular endothelial growth factor expression in vascular smooth muscle cells by preventing the activation of the p38 mitogen-activated protein kinase pathway. Arterioscler Thromb Vasc Biol. 2003 ; 23 (6). 1001-1007.
147. Chan PS, Cervoni P. Prostaglandins, prostacyclin, and thromboxane in cardiovascular diseases. Drug Dev Res. 1986 ; 7 (4). 341-359.
148. Moncada S., Higgs EA Prostaglandins in the pathogenesis and prevention of vascular disease. Blood Rev. 1987 ; 1 (2). 141-145.
149. Iñiguez MA, Cacheiro-Llaguno C., Cuesta N., Díaz-Muñoz MD, Fresno M. Prostanoid function and cardiovascular disease. Arch Physiol Biochem. 2008 ; 114 (3). 201-209.
150. Gleim S., Kasza Z., Martin K., Hwa J. Prostacyclin receptor/ thromboxane receptor interactions and cellular responses in human atherothrombotic disease. Curr Atheroscler Rep. 2009 ; 11 (3). 227-235.
151. Fetalvero KM, Shyu M., Nomikos AP, et al. The prostacyclin receptor induces human vascular smooth muscle cell differentiation via the protein kinase A pathway. Am J Physiol Heart Circ Physiol. 2006 ; 290 (4). H1337 - H1346.
152. Arehart E., Gleim S., Kasza Z., Fetalvero KM, Martin KA, Hwa J. Prostacyclin, atherothrombosis, and cardiovascular disease. Curr Med Chem. 2007 ; 14 (20). 2161-2169.
153. Chataigneau T., Feletou M., Huang PL, Fishman MC, Duhault J., Vanhoutte PM Acetylcholine-induced relaxation in blood vessels from endothelial nitric oxide synthase knockout mice. Br J Pharmacol. 1999 ; 126 (1). 219-226.
154. Sugatani J., Miwa M., Komiyama Y., Ito S. High-density lipoprotein inhibits the synthesis of platelet-activating factor in human vascular endothelial cells. J Lipid Mediat Cell Signal. 1996 ; 13 (1). 73-88.
155. Naqvi TZ, Shah PK, Ivey PA, et al. Evidence that high-density lipoprotein cholesterol is an independent predictor of acute platelet-dependent thrombus formation. Am J Cardiol. 1999 ; 84 (9). 1011-1017.
156. Sellers MM, Stallone JN Sympathy for the devil: the role of thromboxane in the regulation of vascular tone and blood pressure. Am J Physiol Heart Circ Physiol. 2008 ; 294 (5). H1978 - H1986.
157. Davidge ST Prostaglandin H synthase and vascular function. Circ Res. 2001 ; 89 (8). 650-660.
158. Hong BK, Kwon HM, Lee BK, et al. Coexpression of cyclooxygenase-2 and matrix metalloproteinases in human aortic atherosclerotic lesions. Yonsei Med J. 2000 ; 41 (1). 82-88.
159. Tamagaki T., Sawada S., Imamura H., et al. Effects of high-density lipoproteins on intracellular pH and proliferation of human vascular endothelial cells. Atherosclerosis. 1996 ; 123 (1-2). 73-82.
160. Cockerill GW, Saklatvala J., Ridley SJ, et al. High-density lipoproteins differentially modulate cytokine-induced expression of E-selectin and cyclooxygenase-2. Arterioscler Thromb Vasc Biol. 1999 ; 19 (4). 910-917.
161. Herr D., Rodewald M., Fraser HM, et al. Regulation of endothelial proliferation by the renin-angiotensin system in human umbilical vein endothelial cells. Reproduction. 2008 ; 136 (1). 125-130.
162. Shi RZ, Wang JC, Huang SH, Wang XJ, Li QP. Angiotensin II induces vascular endothelial growth factor synthesis in mesenchymal stem cells. Exp Cell Res. 2009 ; 315 (1). 10-15.
163. Ide N., Hirase T., Nishimoto-Hazuku A., Ikeda Y., Node K. Angiotensin II increases expression of IP-10 and the renin-angiotensin system in endothelial cells. Hypertens Res. 2008 ; 31 (6). 1257-1267.
164. Celi A., Del Fiorentino A., Cianchetti S., Pedrinelli R. Tissue factor modulation by angiotensin II: a clue to a better understanding of the cardiovascular effects of renin-angiotensin system blockade ? Endocr Metab Immune Disord Drug Targets. 2008 ; 8 (4). 308-313.
165. Shan H., Bai X., Chen X. Angiotensin II induces endothelial cell senescence via the activation of mitogen-activated protein kinases. Cell Biochem Funct. 2008 ; 26 (4). 459-466.
166. Vinh A., Widdop RE, Drummond GR, Gaspari TA Chronic angiotensin IV treatment reverses endothelial dysfunction in ApoE-deficient mice. Cardiovasc Res. 2008 ; 77 (1). 178-187.
167. Sluimer JC, Gasc JM, Hamming I., et al. Angiotensin-converting enzyme 2 (ACE2) expression and activity in human carotid atherosclerotic lesions. J Pathol. 2008 ; 215 (3). 273-279.
168. Van Linthout S., Spillmann F., Lorenz M., et al. Vascular-protective effects of high-density lipoprotein include the downregulation of the angiotensin II type 1 receptor. Hypertension. 2009 ; 53 (4). 682-687.
169. Lu H., Rateri DL, Feldman DL, et al. Renin inhibition reduces hypercholesterolemia-induced atherosclerosis in mice. J Clin Invest. 2008 ; 118 (3). 984-993.
170. Javeshghani D., Sairam MR, Neves MF, Schiffrin EL, Touyz RM. Angiotensin II induces vascular dysfunction without exacerbating blood pressure elevation in a mouse model of menopause-associated hypertension. J Hypertens. 2006 ; 24 (7). 1365-1373.
171. Xu X., Xiao JC, Luo LF, et al. Effects of ovariectomy and 17beta-estradiol treatment on the renin-angiotensin system, blood pressure, and endothelial ultrastructure. Int J Cardiol. 2008 ; 130 (2). 196-204.
172. Harvey PJ, Morris BL, Su W., Notarius CF, Miller JA, Floras JS Estrogen replacement in postmenopausal women activates the renin-angiotensin system at rest and during simulated orthostatic stress but lowers blood pressure. Am J Hypertens. 2003 ; 16 (S1). 260A - 261A.
173. Ichikawa J., Sumino H., Ichikawa S., Ozaki M. Different effects of transdermal and oral hormone replacement therapy on the renin-angiotensin system, plasma bradykinin level, and blood pressure of normotensive postmenopausal women. Am J Hypertens. 2006 ; 19 (7). 744-749.
174. Umeda M., Ichikawa S., Kanda T., Sumino H., Kobayashi I. Hormone replacement therapy increases plasma level of angiotensin II in postmenopausal hypertensive women. Am J Hypertens. 2001 ; 14 (3). 206-211.
175. Langrish JP, Mills NL, Bath LE, et al. Cardiovascular effects of physiological and standard sex steroid replacement regimens in premature ovarian failure. Hypertension. 2009 ; 53 (5). 805-811.
176. Kalantaridou SN, Naka KK, Papanikolaou E., et al. Impaired endothelial function in young women with premature ovarian failure: normalization with hormone therapy. J Clin Endocrinol Metab. 2004 ; 89 (8). 3907-3913.
177. Connell JM, MacKenzie SM, Freel EM, Fraser R., Davies E. A lifetime of aldosterone excess: long-term consequences of altered regulation of aldosterone production for cardiovascular function. Endocr Rev. 2008 ; 29 (2). 133-154.
178. Perez-Lopez FR Clinical experiences with drosperinone: from reproductive to postmenopausal years. Maturitas. 2008 ; 60 (2). 78-91.
179. Wang M., Zukas AM, Hui Y., Ricciotti E., Puré E., FitzGerald GA Deletion of microsomal prostaglandin E synthase-1 augments prostacyclin and retards atherogenesis. Proc Natl Acad Sci U S A. 2006 ; 103 (39). 14507-14512.
180. Pérez-López FR Vitamin D and its implications for musculoskeletal health in women: an update. Maturitas. 2007 ; 58 (2). 117-137.
181. Giovannucci E., Liu Y., Hollis BW, Rimm EB 25-hydroxyvitamin D and risk of myocardial infarction in men: a prospective study. Arch Intern Med. 2008 ; 168 (11). 1174-1180.
182. Pilz S., Dobnig H., Nijpels G., et al. Vitamin D and mortality in older men and women. Clin Endocrinol (Oxf). 2009 ; 71 (5). 666-672.
183. Yamamoto T., Kozawa O., Tanabe K., et al. 1,25-dihydroxyvitamin D3 stimulates vascular endothelial growth factor release in aortic smooth muscle cells: role of p38 mitogen-activated protein kinase. Arch Biochem Biophys. 2002 ; 398 (1). 1-6.
184. Schleithoff SS, Zittermann A., Tenderich G., Berthold HK, Stehle P., Koerfer R. Vitamin D supplementation improves cytokine profiles in patients with congestive heart failure: a double-blind, randomized, placebo-controlled trial. Am J Clin Nutr. 2006 ; 83 (4). 754-759.
185. Dobnig H., Pilz S., Scharnagl H., et al. Independent association of low serum 25-hydroxyvitamin d and 1,25-dihydroxyvitamin d levels with all-cause and cardiovascular mortality. Arch Intern Med. 2008 ; 168 (12). 1340-1349.
186. Yang R., Barouch LA Leptin signaling and obesity. Cardiovascular consequences. Circulation Res. 2007 ; 101 (6). 545-549.
187. Kralisch S., Bluher M., Paschke R., Stumvoll M., Fasshauer M. Adipokines and adipocyte targets in the future management of obesity and the metabolic syndrome. Mini Rev Med Chem. 2007 ; 7 (1). 39-45.
188. Halberg N., Wernstedt-Asterholm I., Scherer PE The adipocyte as an endocrine cell. Endocrinol Metab Clin North Am. 2008 ; 37 (3). 753-768.
189. Matarese G., Mantzoros C., La Cava A. Leptin and adipocytokines: bridging the gap between immunity and atherosclerosis. Curr Pharm Des. 2007 ; 13 (36). 3676-3680.
190. Rahmouni K., Haynes WG Leptin and the cardiovascular system. Recent Prog Horm Res. 2004 ; 59: 225-244.
191. Fried SK, Ricci MR, Russell CD, Laferrere B. Regulation of leptin production in humans. J Nutrit. 2000 ; 130 (12). 3127S - 3131S.
192. Wallace AM, McMahon AD, Packard CJ, et al. Plasma leptin and the risk of cardiovascular disease in the west of Scotland coronary prevention study (WOSCOPS). Circulation. 2001 ; 104 (25). 3052-3056.
193. Wolk R., Berger P., Lennon RJ, Brilakis ES, Johnson BD, Somers VK Plasma leptin and prognosis in patients with established coronary atherosclerosis. J Am Coll Cardiol. 2004 ; 44 (9). 1819-1824.
194. Shek EW, Brands MW, Hall JE Chronic leptin infusion increases arterial pressure. Hypertension. 1998 ; 31 (1 pt 2). 409-414.
195. Correia ML, Morgan DA, Sivitz WI, Mark AL, Haynes WG Leptin acts in the central nervous system to produce dose-dependent changes in arterial pressure. Hypertension. 2001 ; 37 (3). 936-942.
196. Sierra-Honigmann MR, Nath AK, Murakami C., et al. Biological action of leptin as an angiogenic factor. Science. 1998 ; 28 (5383). 1683-1686.
197. Fruhbeck G. Pivotal role of nitric oxide in the control of blood pressure after leptin administration. Diabetes. 1999 ; 48 (4). 903-908.
198. Lembo G., Vecchione C., Fratta L., et al. Leptin induces direct vasodilation through distinct endothelial mechanisms. Diabetes. 2000 ; 49 (2). 293-297.
199. Kimura K., Tsuda K., Baba A., et al. Involvement of nitric oxide in endothelium-dependent arterial relaxation by leptin. Biochem Biophys Res Commun. 2000 ; 273 (2). 745-749.
200. Gardiner SM, Kemp PA, March JE, Bennett T. Regional haemodynamic effects of recombinant murine or human leptin in conscious rats. Br J Pharmacol. 1999 ; 130 (4). 805-810.
201. Korda M., Kubant R., Patton S., Malinski T. Leptin-induced endothelial dysfunction in obesity. Am J Physiol Heart Circ Physiol. 2008 ; 295 (4). H1514 - H1521.
202. Brydon L., ODonnell K., Wright CE, Wawrzyniak AJ, Wardle J., Steptoe A. Circulating leptin and stress-induced cardiovascular activity in humans. Obesity (Silver Spring). 2008 ; 16 (12). 2642-2647.
203. BeÅtowski J., Jamroz-WiÅ?niewska A., Widomska S. Adiponectin and its role in cardiovascular diseases. Cardiovasc Hematol Disord Drug Targets. 2008 ; 8 (1). 7-46.
204. Okamoto Y., Arita Y., Nishida M., et al. An adipocyte-derived plasma protein, adiponectin, adheres to injured vascular walls. Horm Metab Res. 2000 ; 32 (2). 47-50.
205. Yamauchi T., Kamon J., Ito Y., et al. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature. 2003 ; 423 (6941). 762-769.
206. Bråkenhielm E., Veitonmäki N., Cao R., et al. Adiponectin-induced antiangiogenesis and antitumor activity involve caspase-mediated endothelial cell apoptosis. Proc Natl Acad Sci U S A. 2004 ; 101 (8). 2476-2481.
207. Ukkola O. Santaniemi M. Adiponectin: a link between excess adiposity and associated comorbidities? J Mol Med. 2002 ; 80 (11). 696-702.
208. Maeda N., Shimomura I., Kishida K., et al. Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat Med. 2002 ; 8 (7). 731-737.
209. Moulton KS, Heller E., Konerding MA, Flynn E., Palinski W., Folkman J. Angiogenesis inhibitors endostatin or TNP-470 reduce intimal neovascularization and plaque growth in apolipoprotein E-deficient mice. Circulation. 1999 ; 99 (13). 1726-1732.
210. Kizer J., Barzilay JI, Kuller LH, Gottdiener JS Adiponectin and risk of coronary heart disease in older men and women. J Clin Endocrin Metab. 2008 ; 93 (9). 3357-3364.
211. Chen BH, Song Y., Ding EL, et al. Circulating levels of resistin and risk of type 2 diabetes in men and women: results from two prospective cohorts. Diabetes Care. 2009 ; 32 (2). 329-334.
212. Butler J., Kalogeropoulos A., Georgiopoulou V., et al, for the Health ABC Study. Serum resistin concentrations and risk of new onset heart failure in older persons: the health, aging, and body composition (Health ABC) study. Arterioscler Thromb Vasc Biol. 2009 ; 29 (7). 1144-1149.
213. Frankel DS, Vasan RS, DAgostino RB Sr, et al. Resistin, adiponectin, and risk of heart failure the Framingham offspring study. J Am Coll Cardiol. 2009 ; 53 (9). 754-762.
214. Papadopoulos DP, Perrea D., Thomopoulos C., et al. Masked hypertension and atherogenesis: the impact on adiponectin and resistin plasma levels. J Clin Hypertens (Greenwich). 2009 ; 11 (2). 61-65.
215. Silha JV, Krsek M., Skrha JV, Sucharda P., Nyomba BL, Murphy LJ Plasma resistin, adiponectin and leptin levels in lean and obese subjects: correlations with insulin resistance. Eur J Endocrinol. 2003 ; 149 (4). 331-335.
216. Vendrell J., Broch M., Vilarrasa N., et al. Resistin, adiponectin, ghrelin, leptin, and proinflammatory cytokines: relationships in obesity. Obes Res. 2004 ; 12 (6). 962-971.
217. Lewandowski KC, Szosland K., OCallaghan C., Tan BK, Randeva HS, Lewinski A. Adiponectin and resistin serumlevels in women with polycystic ovary syndrome during oral glucose tolerance test: a significant reciprocal correlation between adiponectin and resistin independent of insulin resistance indices. Mol Genet Metab. 2005 ; 85 (1). 61-69.
218. Travers S., Jeffers B., Bloch C., Hill J., Eckel R. Gender and Tanner stage differences in body composition and insulin sensitivity in early pubertal children. J Clin Endcrinol Metab. 1995 ; 80 (1). 172-178.
219. Moran A., Jacobs D., Steinberger J., et al. Insulin resistance during puberty: results from clamp studies. Diabetes. 1999 ; 48 (10). 2039-2044.
220. Wilkin T., Murphy M. The gender insulin hypothesis. Int J Obes. 2006 ; 30 (7). 1056-1061.
221. Pan W., Cedres L., Liu K. Relationship of clinical diabetes and asymptomatic hyperglycemia to risk of coronary heart disease mortality in men and women. Am J Epidemiol. 1986 ; 123 (3). 504-516.
222. Lundberg V., Stegmayr B., Asplund K. Diabetes as a risk factor for myocardial infarction: population and gender perspectives. J Intern Med. 1997 ; 241 (6). 485-492.
223. Regitz-Zagrosek V., Lehmkuhl E., Mahmoodzadeh S. Gender aspects of the role of the metabolic syndrome as a risk factor for cardiovascular disease. Gend Med. 2007 ; 7 (2). 130-139.
224. Abernethy T., Francis T. Studies on the somatic c polysaccharide of pneumoccus. J Exp Med. 1937 ; 65 (1). 59-73.
225. Manolakou P., Angelopoulou R., Bakoyiannis C. The effects of endogenous and exogenous androgens on cardiovascular disease risk factors and progression. Reprod Biol Endocrinol. 2009 ; 12 (7). 44.
226. Sullivan J. Iron and the sex difference in heart disease risk. Lancet. 1981 ; 1 (8233). 1293-1294.
227. Heinecke J. Oxidants and antioxidants in the pathogenesis of atherosclerosis: implications for the oxidized low density lipoprotein hypothesis. Atherosclerosis. 1998 ; 141 (1). 1-15.
228. Friedrich N., Milman N., Volzke H., Linneberg A., Jorgensen T. Is serum ferritin within the reference range a risk predictor of cardiovascular disease? Br J Nutr. 2009 ; 102 (4). 594-600.
229. Van Der A., Grobbee D., Roest M. Serum ferritin is a risk factor for stroke in postmenopausal women. Stroke. 2003 ; 36 (8). 1637-1641.
230. Sainani G., Sainani R. Homocysteine and its role in the pathogenesis of atherosclerotic vascular disease. J Assoc Physicians India. 2002 ; 50 (suppl 1). 16-23.
231. Selhub J. Homocysteine metabolism. Annu Rev Nutr. 1999 ; 19: 217-246.
232. Wilson K., Lentz S. Mechanisms of the atherogenic effects of elevated homocysteine in experimental models. Semin Vasc Med. 2005 ; 5 (2). 163-171.
233. Bonaa K., Njolstad I., Ueland P. NORVIT trial investigators. Homocysteine lowering and cadiovascular evens after acute myocardial infarction. N Engl J Med. 2006 ; 354 (15). 1578-1588.
234. Papatheodorou L., Weiss N. Vascular oxidant stress and inflammation in hyperhomocysteinemia. Antioxid Redox Signal. 2007 ; 9 (11). 1941-1958.
235. Domagala T., Undas A., Libura M., Szczeklik A. Pathogenesis of vascular disease in hyperhomocysteinaemia. J Cardiovasc Risk. 1998 ; 5 (4). 239-247.
236. Coppola A., Davi G., DeStefano V., Mancini F., Cerbone A., DiMinno G. Homocysteine, coagulation, platelet function, and thrombosis. Semin Thromb Hemost. 2000 ; 26 (3). 243-254.
237. Zhi Y., Huang Y., Li Z., Zhang R. Hypermethylation of estrogen receptor-alpha gene and high homocysteine in atheromatosis patients. Wei Sheng Yan Jiu. 2008 ; 37 (3). 314-317.
238. Bonassi Machado R., Baracat EC, Fernandes CE, Lakryc EM, Rodrigues De Lima G. Effects of estrogen and estrogenprogestogen therapy on homocysteine levels and their correlation with carotid vascular resistance. Gynecol Endocrinol. 2007 ; 23 (11). 619-624.
239. Nakhai Pour HR, Grobbee DE, Muller M., Emmelot-Vonk M., van der Schouw YT Serum sex hormone and plasma homocysteine levels in middle-aged and elderly men. Eur J Endocrinol. 2006 ; 155 (6). 887-893.